Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (opens new window)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Avots‎: Cancer 2013;119(21):3784-7.

Raksts indeksēts‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (opens new window)

Low dose bolus aminocaproic acid: an alternative to platelet transfusion in thrombocytopenia? (opens new window)

Chakrabarti S, Varma S, Singh S, Kumari S

Avots‎: Eur J Haematol 1998;60(5):313-4.

Raksts indeksēts‎: PubMed 9654162

DOI‎: 10.1111/j.1600-0609.1998.tb01046.x

https://www.ncbi.nlm.nih.gov/pubmed/9654162 (opens new window)

The use of antifibrinolytics in pediatric patients with hypoproliferative thrombocytopenia. (opens new window)

Delaney M, Matthews DC, Gernsheimer TB

Avots‎: Pediatr Blood Cancer 2017;64(12):e26641.

Raksts indeksēts‎: PubMed 28544698

DOI‎: 10.1002/pbc.26641

https://www.ncbi.nlm.nih.gov/pubmed/28544698 (opens new window)

Preliminary experience with epsilon aminocaproic acid for treatment of intractable upper tract hematuria in children with hematological disorders. (opens new window)

Kaye JD, Smith EA, Kirsch AJ, Cerwinka WH, Elmore JM

Avots‎: J Urol 2010;184(3):1152-7.

Raksts indeksēts‎: PubMed 20650477

DOI‎: 10.1016/j.juro.2010.05.020

https://www.ncbi.nlm.nih.gov/pubmed/20650477 (opens new window)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (opens new window)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Avots‎: Leuk Lymphoma 1995;19(1-2):141-4.

Raksts indeksēts‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (opens new window)

Pediatric off-label use of recombinant factor VIIa. (opens new window)

Alten JA, Benner K, Green K, Toole B, Tofil NM, Winkler MK.

Avots‎: Pediatrics 2009;123(3):1066-72.

Raksts indeksēts‎: PubMed 19255041

DOI‎: 10.1542/peds.2008-1685

https://www.ncbi.nlm.nih.gov/pubmed/19255041 (opens new window)

Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience. (opens new window)

Bhat S, Yadav SP, Anjan M, Dinand V, Sachdeva A.

Avots‎: Indian J Pediatr 2011;78(8):961-8.

Raksts indeksēts‎: PubMed 21328080

DOI‎: 10.1007/s12098-011-0364-6

https://www.ncbi.nlm.nih.gov/pubmed/21328080 (opens new window)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (opens new window)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Avots‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Raksts indeksēts‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (opens new window)

Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. (opens new window)

Croteau SE, Nakar C, Neufeld EJ, Shapiro A, Cooper DL

Avots‎: Pediatr Blood Cancer 2016;63(10):1822-8.

Raksts indeksēts‎: PubMed 27232114

DOI‎: 10.1002/pbc.26082

https://www.ncbi.nlm.nih.gov/pubmed/27232114 (opens new window)

Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia. (opens new window)

Das P, Carcao M, Hitzler J

Avots‎: Pediatr Blood Cancer 2006;47(2):206-9.

Raksts indeksēts‎: PubMed 16007583

DOI‎: 10.1002/pbc.20467

https://www.ncbi.nlm.nih.gov/pubmed/16007583 (opens new window)

A comprehensive review of rFVIIa use in a tertiary care pediatric center. (opens new window)

Heller M, Lau W, Pazmino-Canizares J, Brandão LR, Carcao M

Avots‎: Pediatr Blood Cancer 2008;50(5):1013-7.

Raksts indeksēts‎: PubMed 17960639

DOI‎: 10.1002/pbc.21375

https://www.ncbi.nlm.nih.gov/pubmed/17960639 (opens new window)

Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. (opens new window)

Kurekci AE, Atay AA, Okutan V, Yavuz ST, Ozcan O

Avots‎: Blood Coagul Fibrinolysis 2005;16(2):145-7.

Raksts indeksēts‎: PubMed 15741803

DOI‎: 10.1097/01.mbc.0000161569.66764.70

https://www.ncbi.nlm.nih.gov/pubmed/15741803 (opens new window)

Off-label use of recombinant factor VIIa in pediatric patients. (opens new window)

McQuilten ZK, Barnes C, Zatta A, Phillips LE; Haemostasis Registry Steering Committee

Avots‎: Pediatrics 2012;129(6):e1533-40.

Raksts indeksēts‎: PubMed 22641758

DOI‎: 10.1542/peds.2011-2561

https://www.ncbi.nlm.nih.gov/pubmed/22641758 (opens new window)

Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) registry (2004-2008). (opens new window)

Neufeld EJ, Saxena K, Kessler CM, Cooper DL; HTRS Investigators

Avots‎: Pediatr Blood Cancer 2013;60(7):1178-83.

Raksts indeksēts‎: PubMed 23335449

DOI‎: 10.1002/pbc.24472

https://www.ncbi.nlm.nih.gov/pubmed/23335449 (opens new window)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (opens new window)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Avots‎: Med Oncol 2010;27(1):16-9.

Raksts indeksēts‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (opens new window)

Successful treatment of acute lymphoblastic leukemia with l-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child. (opens new window)

Ucar C, Caliskan U

Avots‎: Pediatr Hematol Oncol 2006;23(4):339-45.

Raksts indeksēts‎: PubMed 16621776

DOI‎: 10.1080/08880010600631987

https://www.ncbi.nlm.nih.gov/pubmed/16621776 (opens new window)

Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder. (opens new window)

Yilmaz D, Karapinar B, Balkan C, Akisü M, Kavakli K.

Avots‎: Pediatr Hematol Oncol 2008;25(4):301-11.

Raksts indeksēts‎: PubMed 18484474

DOI‎: 10.1080/08880010802016904

https://www.ncbi.nlm.nih.gov/pubmed/18484474 (opens new window)

The use of DDAVP in children with bleeding disorders. (opens new window)

Ben-Ami T, Revel-Vilk S

Avots‎: Pediatr Blood Cancer 2013;60 Suppl 1:S41-3.

Raksts indeksēts‎: PubMed 23109357

DOI‎: 10.1002/pbc.24335

https://www.ncbi.nlm.nih.gov/pubmed/23109357 (opens new window)

Treatment of refractory thrombocytopenic bleeding with 1-desamino-8-D-arginine vasopressin (desmopressin). (opens new window)

Kobrinsky NL, Tulloch H

Avots‎: J Pediatr 1988;112(6):993-6.

Raksts indeksēts‎: PubMed 3373409

DOI‎: 10.1016/s0022-3476(88)80234-8

https://www.ncbi.nlm.nih.gov/pubmed/3373409 (opens new window)

The use of Tachosil as hemostatic sealant in nephron sparing surgery for Wilms tumor: preliminary observations. (opens new window)

Mele E, Ceccanti S, Schiavetti A, Bosco S, Masselli G, Cozzi DA

Avots‎: J Pediatr Surg 2013;48(3):689-94.

Raksts indeksēts‎: PubMed 23480936

DOI‎: 10.1016/j.jpedsurg.2013.01.019

https://www.ncbi.nlm.nih.gov/pubmed/23480936 (opens new window)